Thema: TW0006919004
Caliway Biopharmaceuticals C, TW0006919004
stock-market-6693060.jpg - Foto: THN
Caliway Biopharmaceuticals C stock sits at TWD 76.50, 1.86 percent above its low
Caliway's next results are scheduled for November 11, 2026. Caliway Biopharmaceuticals C stock costs TWD 76.50 on October 13, 2026, minus 0.91 percent versus the prior close.
ad-hoc-news.de, heute 14:39 Uhr
Caliway Biopharmaceuticals C, TW0006919004
Caliway started phase 3: analyst targets Caliway Biopharmaceuticals ...
For Caliway Biopharmaceuticals C stock this means 69.60 percent reached 150 mL. Q2 revenue was TWD 3.57 million and net loss TWD 222.52 million.
ad-hoc-news.de, heute 10:36 Uhr
Caliway Biopharmaceuticals C, TW0006919004
Caliway Biopharmaceuticals C stock at TWD 77.20 on October ...
Q2 revenue was TWD 3.57 million, net loss TWD 222.52 million. Caliway Biopharmaceuticals C stock was TWD 77.20 on October 12, 2026 versus TWD 75.10.
ad-hoc-news.de, 12.10.26 14:39 Uhr
Caliway Biopharmaceuticals C, TW0006919004
Caliway reported phase 2 results: what it means for Caliway ...
CBL-0202DD achieved its primary endpoint on September 21, 2026. For Caliway Biopharmaceuticals C stock, this means 3 phase 3 studies.
ad-hoc-news.de, 12.10.26 10:42 Uhr
Caliway Biopharmaceuticals C, TW0006919004
Caliway starts phase 3 trial: what it means for Caliway ...
Caliway began a 320-person phase 3 trial on September 23, 2026. Caliway Biopharmaceuticals C stock had TWD 120.6 billion value on October 8, 2026.
ad-hoc-news.de, 09.10.26 12:01 Uhr
Caliway Biopharmaceuticals C, TW0006919004
Canada authorized Caliway phase 3 amendment: what it means ...
Canada approved a phase 3 amendment on September 21, 2026. On October 8, 2026, Caliway Biopharmaceuticals C stock had TWD 120.6 billion market value.
ad-hoc-news.de, 08.10.26 12:28 Uhr
Caliway Biopharmaceuticals C, TW0006919004
Caliway Biopharmaceuticals stock reports phase 2 obesity ...
